Converge Bio, an innovative startup focused on AI-driven drug discovery, has successfully raised $25 million in a Series A funding round. The investment is spearheaded by Bessemer Venture Partners and features contributions from prominent executives at Meta, OpenAI, and Wiz. This significant funding will empower Converge Bio to advance its groundbreaking technologies and enhance its capabilities in the biotech arena, aiming to revolutionize the way drugs are developed. With a team backed by leaders from some of the most influential tech companies, Converge Bio is poised to make a notable impact in the pharmaceutical industry.